Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

$Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies$

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.

13 Jan 2015

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

Researchers from the Republic of Korea have found that epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations can occur concomitantly in a proportion of patients with non-small-cell lung cancer.

12 Jan 2015

$ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL$

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.

8 Jan 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS).

6 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Soligenix closes previously announced registered public offering

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.

25 Dec 2014

TUM researchers discover new mechanism for regulating programmed cell death

Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor growth. Now, researchers at Technische Universität München have discovered a previously unknown mechanism for regulating programmed cell death.

18 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

UC Davis researchers uncover complex relationship between p53 and Rbm38 proteins

Scientists have long known the p53 protein suppresses tumors. However, a recent animal study by UC Davis researchers has uncovered a complicated relationship between p53 and another protein, Rbm38, highlighting how the body calibrates protein levels. Too much Rbm38 reduces p53 levels, increasing the risk of cancer.

16 Dec 2014

Apheresis: A potent therapeutic in extracorporeal photopherisis

Apheresis, the simple process of drawing blood, becomes a powerful therapeutic in extracorporeal photopherisis (ECP) according to clinicians and scientists who met at the NIH State of the Science Symposium in Therapeutic Apheresis. Nora Ratcliffe, MD, of Dartmouth Hitchcock, looked at current methodology and opportunities for research in a paper recently published in Transfusion Medicine Review, titled "National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific Opportunities in Extracorporeal Photopheresis."

14 Dec 2014

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.

13 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014

Study finds that disarray in methylation helps tumors adapt to changing circumstances

The genetic tumult within cancerous tumors is more than matched by the disorder in one of the mechanisms for switching cells' genes on and off, scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard report in a new study.

9 Dec 2014

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

CTI BioPharma Corp. today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Findings open new avenues for research to predict risk of therapy-related AML

For a small percentage of cancer patients, treatment aimed at curing the disease leads to a form of leukemia with a poor prognosis. Conventional thinking goes that chemotherapy and radiation therapy induce a barrage of damaging genetic mutations that kill cancer cells yet inadvertently spur the development of acute myeloid leukemia (AML), a blood cancer.

8 Dec 2014

Lymphoma News and Research

Further Reading

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Soligenix closes previously announced registered public offering

TUM researchers discover new mechanism for regulating programmed cell death

Lilly receives FDA approval for CYRAMZA (ramucirumab)

UC Davis researchers uncover complex relationship between p53 and Rbm38 proteins

Apheresis: A potent therapeutic in extracorporeal photopherisis

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

PD-1, PD-L1 differentially expressed in NSCLC

Study finds that disarray in methylation helps tumors adapt to changing circumstances

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Findings open new avenues for research to predict risk of therapy-related AML

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News